• 1. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 2. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 3. An integrated system for field analysis of Cd(ii) and Pb(ii) via preconcentration using nano-TiO2/cellulose paper composite and subsequent detection with a portable X-ray fluorescence spectrometer?
  Xiaofeng Lin RSC Adv., 2016,6, 9002-9006
• 4. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 5. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378

Comprehensive Overview of (S) Nifuratel (CAS No. 951787-74-9): Mechanism, Applications, and Research Insights

(S) Nifuratel, identified by its CAS number 951787-74-9, is a chiral derivative of the broad-spectrum antimicrobial agent Nifuratel. This compound has garnered significant attention in pharmaceutical research due to its enhanced enantiomeric purity and potential therapeutic advantages. Unlike its racemic counterpart, the (S)-enantiomer exhibits optimized pharmacokinetic properties, making it a focal point for drug development targeting microbial infections, particularly in urogenital and gastrointestinal systems.

The mechanism of action of (S) Nifuratel revolves around its ability to inhibit microbial DNA synthesis by interfering with nitroreductase enzymes. This specificity aligns with current trends in precision medicine, where researchers prioritize compounds with minimal off-target effects. Recent studies highlight its efficacy against drug-resistant strains, addressing the global concern of antimicrobial resistance (AMR)—a topic dominating healthcare discussions in 2024. Its low toxicity profile further positions it as a candidate for repurposing in emerging therapeutic areas.

From a synthetic chemistry perspective, CAS 951787-74-9 represents a milestone in asymmetric synthesis. The compound’s stereocenter at the C-5 position is critical for its bioactivity, a feature often explored in structure-activity relationship (SAR) studies. Analytical techniques like chiral HPLC and X-ray crystallography are routinely employed to validate its enantiopurity, reflecting the industry’s shift toward quality-by-design (QbD) principles.

Market analytics reveal growing interest in (S) Nifuratel across pharmaceutical excipients and API formulation sectors. Search engine data indicates frequent queries such as "(S) Nifuratel vs racemic Nifuratel" and "CAS 951787-74-9 solubility," underscoring demand for comparative and physicochemical data. Regulatory filings in Europe and Asia-Pacific regions further validate its commercial viability, with patents emphasizing its synergistic combinations with probiotics—a nod to the booming microbiome therapeutics market.

Ongoing clinical trials investigate (S) Nifuratel’s role in chronic pelvic inflammation and bacterial vaginosis, conditions with high unmet medical needs. Its anti-inflammatory properties, mediated via NF-κB pathway modulation, have sparked parallel research in autoimmune disorders. These applications resonate with the patient-centric healthcare movement, where efficacy and safety are paramount.

In conclusion, (S) Nifuratel (951787-74-9) exemplifies the convergence of chiral pharmacology and antimicrobial innovation. Its multifaceted profile—spanning synthetic accessibility, mechanistic clarity, and therapeutic versatility—makes it a compelling subject for researchers navigating the challenges of infectious disease management and drug development in the 21st century.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)